Policy & Medicine - Legal, Regulatory, and Compliance Issues

In addition to the recent Amgen Settlement, the federal government announced several other settlements with pharmaceutical…

As we noted earlier this year, the U.S. Supreme Court agreed to hear a case to decide whether agreements between brand-name…

The Centers for Medicare and Medicaid Services (CMS) recently released a 114-page proposed rule that would loosen certain…

The Healthcare Leadership Council a coalition of chief executives from all disciplines within American healthcare, is hosting a…

This past summer, Congress passed and President Obama signed the Food and Drug Administration Safety and Innovation Act (FDASIA)…

As we have covered numerous times on this website, in 2009, the State of Massachusetts enacted the Massachusetts Pharmaceutical…

Now that stakeholders have had a few weeks to read the final rules and begin implementing the Physician Payment Sunshine Act, we…

According to a recent survey, some physicians actually know less about the Sunshine Act provision of the Patient Protection and…

Late last year, we reported that GlaxoSmithKline promised to make detailed data from its clinical trials available to independent…

Pharm Exec recently asked the Tufts Center for the Study of Drug Development (TCSDD) to summarize new survey research—partly…